Loss of von Hippel-Lindau Protein (VHL) Increases Systemic Cholesterol Levels through Targeting Hypoxia-Inducible Factor 2α and Regulation of Bile Acid Homeostasis

被引:25
|
作者
Ramakrishnan, Sadeesh K. [1 ]
Taylor, Matthew [1 ]
Qu, Aijuan [4 ]
Ahn, Sung-Hoon [4 ]
Suresh, Madathilparambil V. [3 ]
Raghavendran, Krishnan [3 ]
Gonzalez, Frank J. [4 ]
Shah, Yatrik M. [1 ,2 ]
机构
[1] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI USA
[4] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
OBSTRUCTIVE SLEEP-APNEA; FARNESOID-X-RECEPTOR; DENSITY-LIPOPROTEIN RECEPTOR; 7-ALPHA-HYDROXYLASE GENE; INTERMITTENT HYPOXIA; TRANSCRIPTION FACTOR; LUNG CONTUSION; MESSENGER-RNA; LDL RECEPTOR; RISK-FACTORS;
D O I
10.1128/MCB.01441-13
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesterol synthesis is a highly oxygen-dependent process. Paradoxically, hypoxia is correlated with an increase in cellular and systemic cholesterol levels and risk of cardiovascular diseases. The mechanism for the increase in cholesterol during hypoxia is unclear. Hypoxia signaling is mediated through hypoxia-inducible factor 1 alpha (HIF-1 alpha) and HIF-2 alpha. The present study demonstrates that activation of HIF signaling in the liver increases hepatic and systemic cholesterol levels due to a decrease in the expression of cholesterol hydroxylase CYP7A1 and other enzymes involved in bile acid synthesis. Specifically, activation of hepatic HIF-2 alpha (but not HIF-1 alpha) led to hypercholesterolemia. HIF-2 alpha repressed the circadian expression of Rev-erb alpha, resulting in increased expression of E4BP4, a negative regulator of Cyp7a1. To understand if HIF-mediated decrease in bile acid synthesis is a physiologically relevant pathway by which hypoxia maintains or increases systemic cholesterol levels, two hypoxic mouse models were assessed, an acute lung injury model and mice exposed to 10% O-2 for 3 weeks. In both models, cholesterol levels increased with a concomitant decrease in expression of genes involved in bile acid synthesis. The present study demonstrates that hypoxic activation of hepatic HIF-2 alpha leads to an adaptive increase in cholesterol levels through inhibition of bile acid synthesis.
引用
收藏
页码:1208 / 1220
页数:13
相关论文
共 50 条
  • [31] Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
    Cockman, ME
    Masson, N
    Mole, DR
    Jaakkola, P
    Chang, GW
    Clifford, SC
    Maher, ER
    Pugh, CW
    Ratcliffe, PJ
    Maxwell, PH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) : 25733 - 25741
  • [32] Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α
    Okumura, Fumihiko
    Uematsu, Keiji
    Byrne, Stuart D.
    Hirano, Mie
    Joo-Okumura, Akiko
    Nishikimi, Akihiko
    Shuin, Taro
    Fukui, Yoshinori
    Nakatsukasa, Kunio
    Kamura, Takumi
    MOLECULAR AND CELLULAR BIOLOGY, 2016, 36 (12) : 1803 - 1817
  • [33] Hypoxia-inducible factor-1α, von Hippel-Lindau protein, and heat shock protein expression in ophthalmic pterygium and normal conjunctiva
    Pagoulatos, Dionysios
    Pharmakakis, Nikolaos
    Lakoumentas, John
    Assimakopoulou, Martha
    MOLECULAR VISION, 2014, 20 : 441 - 457
  • [34] The COP9/signalosome increases the efficiency of von hippel-lindau protein ubiquitin ligase-mediated hypoxia-inducible factor-α ubiquitination
    Miyauchi, Yasuhiro
    Kato, Michiko
    Tokunaga, Fuminori
    Iwai, Kazuhiro
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (24) : 16622 - 16631
  • [35] Dynamic, site-specific interaction of hypoxia-inducible factor-1α with the von Hippel-Lindau tumor suppressor protein
    Yu, F
    White, SB
    Zhao, Q
    Lee, FS
    CANCER RESEARCH, 2001, 61 (10) : 4136 - 4142
  • [36] Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
    Michael Ohh
    Cheol Won Park
    Mircea Ivan
    Michael A. Hoffman
    Tae-You Kim
    L. Eric Huang
    Nikola Pavletich
    Vincent Chau
    William G. Kaelin
    Nature Cell Biology, 2000, 2 : 423 - 427
  • [37] Belzutifan, an oral hypoxia-inducible factor 2α inhibitor, for Von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors
    Else, T.
    Jonasch, E.
    Iliopoulos, O.
    Rathmell, W. K.
    Narayan, V. K.
    Maughan, B. L.
    Oudard, S.
    Fu, W.
    Liu, Y.
    Perini, R. F.
    Linehan, W. M.
    Srinivasan, R.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 172 - 172
  • [38] Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1α
    Sun, X
    Kanwar, JR
    Leung, E
    Vale, M
    Krissansen, GW
    GENE THERAPY, 2003, 10 (25) : 2081 - 2089
  • [39] von Hippel-Lindau β-domain-luciferase fusion protein as a bioluminescent hydroxyproline sensor for a hypoxia-inducible factor prolyl hydroxylase assay
    Hong, Sungchae
    Yum, Soohwan
    Ha, Nam-Chul
    Jung, Yunjin
    ANALYTICAL BIOCHEMISTRY, 2010, 407 (02) : 220 - 225
  • [40] Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces "angiogenic switch off" in a hepatoma mouse model
    Iwamoto, Hideki
    Nakamura, Toru
    Koga, Hironori
    Izaguirre-Carbonell, Jesus
    Kamisuki, Shinji
    Sugawara, Fumio
    Abe, Mitsuhiko
    Iwabata, Kazuki
    Ikezono, Yu
    Sakaue, Takahiko
    Masuda, Atsutaka
    Yano, Hirohisa
    Ohta, Keisuke
    Nakano, Masahito
    Shimose, Shigeo
    Shirono, Tomotake
    Torimura, Takuji
    MOLECULAR THERAPY-ONCOLYTICS, 2015, 2 : 15020